Table II.
Prognostic factors for overall and progression-free survival.
| Overall survival | Progression-free survival | ||||||
|---|---|---|---|---|---|---|---|
| Prognostic factors | n | Median (months) | HR (95% CI) | P-value | Median (months) | HR (95% CI) | P-value |
| Total | 47 | 22.5 | 11.3 | ||||
| Age, years | 0.586 | 0.615 | |||||
| <79 | 23 | 22.5 | 1 | 11.3 | 1 | ||
| ≥79 | 24 | 17.5 | 1.22 (0.59–2.53) | 9.5 | 1.19 (0.61–2.31) | ||
| Clinical stage | 0.270 | 0.292 | |||||
| III | 8 | 59.7 | 1 | 17.9 | 1 | ||
| IV | 39 | 17.5 | 1.80 (0.63–5.16) | 9.5 | 1.66 (0.64–4.31) | ||
| T classification | 0.684 | 0.897 | |||||
| 1–3 | 19 | 17.9 | 1 | 11.3 | 1 | ||
| 4 | 28 | 22.5 | 0.86 (0.42–1.78) | 10.4 | 1.05 (0.53–2.07) | ||
| Midline involvement | 0.433 | 0.083 | |||||
| No | 23 | 28.3 | 1 | 17.9 | 1 | ||
| Yes | 24 | 16.2 | 1.33 (0.65–2.73) | 6.9 | 1.80 (0.92–3.53) | ||
| Node positivity | 0.990 | 0.650 | |||||
| No | 13 | 27.9 | 1 | 17.9 | 1 | ||
| Yes | 34 | 19.8 | 1.00 (0.45–2.18) | 8.9 | 1.19 (0.57–2.48) | ||
| Multiple nodes | 0.538 | 0.538 | |||||
| No | 15 | 28.3 | 1 | 17.9 | 1 | ||
| Yes | 32 | 17.5 | 1.28 (0.58–2.80) | 8.9 | 1.25 (0.61–2.57) | ||
| Contralateral node | 0.330 | 0.306 | |||||
| No | 33 | 27.9 | 1 | 11.3 | 1 | ||
| Yes | 14 | 17.5 | 1.46 (0.68–3.12) | 7.7 | 1.44 (0.71–2.90) | ||
| Level Ia involvement | 0.008 | 0.001 | |||||
| No | 38 | 28.3 | 1 | 12.3 | 1 | ||
| Yes | 9 | 16.5 | 2.83 (1.27–6.33) | 4.8 | 3.56 (1.60–7.94) | ||
| Level III–V involvement | 0.099 | 0.052 | |||||
| No | 30 | 28.3 | 1 | 15.0 | 1 | ||
| Yes | 17 | 14.3 | 1.85 (0.88–3.88) | 8.9 | 1.95 (0.98–3.87) | ||
| ENIa | 0.038 | 0.005 | |||||
| No | 25 | 59.7 | 1 | 21.6 | 1 | ||
| Yes | 22 | 16.2 | 2.16 (1.03–4.55) | 7.7 | 2.65 (1.32–5.33) | ||
a
Nodal involvement at uncommon levels, i.e., anterior extension to level Ia and/or inferior extension to levels III–V. CI, confidence interval; ENI, extensive nodal involvement; HR, hazards ratio.